A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Acronyms PRISM303
- Sponsors BioMarin Pharmaceutical
- 01 Dec 2015 Planned end date changed from 1 Sep 2016 to 1 Apr 2017, as reported by ClinicalTrials.gov.
- 01 Dec 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017, as reported by ClinicalTrials.gov.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.